Fig. 4: GlycoTyper Method for the serum analysis of specific glycoproteins.
From: Spatial omics-based machine learning algorithms for the early detection of hepatocellular carcinoma
a Slides are spotted with 16 antibodies (top to bottom in columns) to the following antibodies: (1) anti-Alpha 1 Antitrypsin, (2) anti- Alpha 1B-Glycopotein, (3) anti-alpha 1-Acid Glycoprotein, (4) anti-Alpha-2-Macroglobulin, (5) anti-Angiotensinogen II/III, (6) anti-Apolipoprotein D, (7) anti-Apolipoprotein H (ApoH), (8) anti-Ceruloplasmin, (9) anti-Clusterin, 10) anti-Fetuin, 11) anti-Haptoglobin, 12) anti-Hemopexin, (13) anti histidine-proline rich glycoprotein; (14) anti-IgG, (15) anti-Transferrin; (16) anti-Vitamin D Binding Protein. B-D) Example of GlycoTyper data for the 16 captured proteins for N-glycan at 2539.881 (b, e), N-glycan at 2174.654 (c, f) and N-glycan at 1809.639 (d, g). b–d are from patients with HCC, while e–g are from patient with cirrhosis. h Bar graph with individual data points showing the mean (with SD) level of N-glycan at 2539.907 on haptoglobin; i Bar graph with individual data points showing the mean (with SD) level of N-glycan at 1663.581 on transferrin. j, k Similar analysis on angiotensinogen (j) hemopexin (k). l ROC curves for Model G, AFP and AFP-L3 of discriminant ability to classify all or early-stage HCC from cirrhosis. Where statistical difference exists, the p value is provided and error bars indicate the standard deviation.
